A Phase I-II Study of COX-2 Inhibitor, Celebrex (Celecoxib) and Chemoradiation in Patients With Locally Advanced Cervical Cancer: Primary Endpoint Analysis of RTOG 0128

Reviewer: Voika BarAd, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 19 de octubre del 2005

Translation for this article does not exist

Blogs

Cancer and Hair Loss
by Bob Riter
February 11, 2016